The overall aim of this Center is to provide molecular, genetic, chemical and analytical knowledge and expertise to create new and enhance previously funded drug abuse research at this and neighboring universities. These Cores will provide up-to-date and innovative expertise that is somewhat oblique to the methodologies used in previously funded research. This will result in new collaborative research and enhance previously funded research in ways that could not have been contemplated just a few years ago. Cores in synthetic and analytical chemistry, genetics, genetically engineered altered mice/viral vectors, and receptor function will provide the opportunity for funded researchers to broaden the scope of their work to transform knowledge in very creative ways. The inclusion of chemistry, genetics and analytical Cores will fill a major void in our many research projects. The ability to continue to provide genetically altered mice with appropriate genotyping, etc., and the inclusion of expertise in viral vector technology are seen as major assets of this Center. Being able to have a collaborator elucidate receptor function changes for a substance found to alter behavior or craving for a drug provides the atmosphere for new and creative research. This type of collaboration among scientists at different institutions is rare and would take many months or years if in fact collaboration could be established at all. In this Center this type of collaboratin will be the norm. We are committed to provide considerable institutional support such as the use of an up-to-date imaging center and a forensic toxicology laboratory established by the university. We will match dollar for dollar the pilot project program and provide administrative support beyond the modest amount requested. The Cores will also be utilized by NlDA-funded investigators at the University of Virginia and George Mason University. Scholars at the relatively new Pharmacy School at Hampton University have expressed interest (letter from the dean) in the utilization of these Cores as they establish their research programs. We will also share all aspects of this Center with scientists throughout the country.

Public Health Relevance

Drug abuse and addiction produce a major human and financial burden on society. The complexities of the diseases associated with substance abuse and addiction are being appreciated more and more all the time. It is obvious that a comprehensive approach as described in this application is needed to determine the best way to prevent and treat these diseases.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Center Core Grants (P30)
Project #
5P30DA033934-02
Application #
8774885
Study Section
Special Emphasis Panel (ZDA1-EXL-T (02))
Program Officer
Lynch, Minda
Project Start
2013-12-01
Project End
2018-11-30
Budget Start
2014-12-01
Budget End
2015-11-30
Support Year
2
Fiscal Year
2015
Total Cost
$537,649
Indirect Cost
$185,092
Name
Virginia Commonwealth University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Donvito, Giulia; Nass, Sara R; Wilkerson, Jenny L et al. (2018) The Endogenous Cannabinoid System: A Budding Source of Targets for Treating Inflammatory and Neuropathic Pain. Neuropsychopharmacology 43:52-79
Wolstenholme, Jennifer T; Bowers, M Scott; Pais, Alexander B et al. (2018) Dietary Omega-3 Fatty Acids Differentially Impact Acute Ethanol-Responsive Behaviors and Ethanol Consumption in DBA/2J Versus C57BL/6J Mice. Alcohol Clin Exp Res :
Hermes, Douglas J; Xu, Changqing; Poklis, Justin L et al. (2018) Neuroprotective effects of fatty acid amide hydrolase catabolic enzyme inhibition in a HIV-1 Tat model of neuroAIDS. Neuropharmacology 141:55-65
Mischel, Ryan A; Dewey, William L; Akbarali, Hamid I (2018) Tolerance to Morphine-Induced Inhibition of TTX-R Sodium Channels in Dorsal Root Ganglia Neurons Is Modulated by Gut-Derived Mediators. iScience 2:193-209
Shin, Myungsun; Snyder, Helena W; Donvito, Giulia et al. (2018) Liposomal Delivery of Diacylglycerol Lipase-Beta Inhibitors to Macrophages Dramatically Enhances Selectivity and Efficacy in Vivo. Mol Pharm 15:721-728
Gonek, Maciej; McLane, Virginia D; Stevens, David L et al. (2018) CCR5 mediates HIV-1 Tat-induced neuroinflammation and influences morphine tolerance, dependence, and reward. Brain Behav Immun 69:124-138
Curry, Zachary A; Wilkerson, Jenny L; Bagdas, Deniz et al. (2018) Monoacylglycerol Lipase Inhibitors Reverse Paclitaxel-Induced Nociceptive Behavior and Proinflammatory Markers in a Mouse Model of Chemotherapy-Induced Neuropathy. J Pharmacol Exp Ther 366:169-183
Cooper, Ziva D; Poklis, Justin L; Liu, Fei (2018) Methodology for controlled administration of smoked synthetic cannabinoids JWH-018 and JWH-073. Neuropharmacology 134:92-100
Withey, Sarah L; Hill, Rob; Lyndon, Abigail et al. (2017) Effect of Tamoxifen and Brain-Penetrant Protein Kinase C and c-Jun N-Terminal Kinase Inhibitors on Tolerance to Opioid-Induced Respiratory Depression in Mice. J Pharmacol Exp Ther 361:51-59
Wolf, Carl E; Poklis, Justin L; Cumpston, Kirk et al. (2017) Acute dilated cardiomyopathy and myocardial injury after combined 4-fluoroamphetamine and modafinil ingestion. Drug Test Anal 9:657-659

Showing the most recent 10 out of 93 publications